Granted Patent B2

US 12,329,752 · App. 17/463,258 · Granted Jun 17, 2025

Inventors: Zeus Pendon (Woburn, MA); Steven Dinh (Burlington, MA)

Assignee: AZURITY PHARMACEUTICALS, INC.

A61K31/4439A61K9/0053A61K31/351A61K47/10A61K47/12A61K47/24A61K47/26A61K47/34A61K47/38A61P1/04C07D401/12

Abstract

Claims (27)

1. An oral liquid suspension of a proton pump inhibitor consisting essentially of:

a proton pump inhibitor;

1.0%-4.0% w/v of a poloxamer;

a suspending agent, wherein the suspending agent is (i) sodium carboxymethylcellulose (CMC) or (ii) a combination of sodium CMC and microcrystalline cellulose, and wherein the suspending agent is present in the suspension in an amount of about 0.5% to 5% w/v;

8.0%-8.8% w/v of an acid neutralizing agent;

0.1%-0.3% w/v of a defoamer;

0.2%-1.2% w/v of a preservative:

water;

optionally a buffer that maintains a pH of 8 to 9.5; and

optionally one or more selected from, a sweetener, a coloring agent, and a flavoring agent;

wherein the oral liquid suspension is homogenous and stable for at least 30 days at ambient conditions and at refrigerated temperature conditions, and wherein the suspension is formulated to be orally administered to a human subject in need thereof.

2. The oral liquid suspension of claim 1 , wherein the proton pump inhibitor is omeprazole or lansoprazole.

3. The oral liquid suspension of claim 1 , wherein the proton pump inhibitor is omeprazole and is present in the suspension at about 2 mg/ml.

4. The oral liquid suspension of claim 1 , wherein the poloxamer has a number average molecular weight of about 7000 to about 10,000 Da and an ethylene glycol content of about 80 wt % to about 85 wt %.

5. The oral liquid suspension of claim 1 , wherein the poloxamer is poloxamer 188.

6. The oral liquid suspension of claim 1 , wherein the sodium CMC is present in the suspension at 1.0%-2.0% w/v.

7. The oral liquid suspension of claim 1 , wherein the suspending agent is a combination of sodium CMC and microcrystalline cellulose.

8. The oral liquid suspension of claim 7 , wherein the combination of sodium CMC and microcrystalline cellulose is present in the liquid diluent at about 4.0% w/v.

9. The oral liquid suspension of claim 1 , wherein the preservative is one or more of the group consisting of: benzyl alcohol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), citric acid, sodium benzoate, benzoic acid, sodium bisulfate, sodium metabisulfite, sodium sulfite, parabens, potassium sorbate, vanillin, and pharmaceutically acceptable salts thereof.

10. The oral liquid suspension of claim 9 , wherein the preservative is benzyl alcohol.

11. The oral liquid suspension of claim 10 , wherein the benzyl alcohol is present at about 0.4% to about 0.6% w/v in the suspension.

12. The oral liquid suspension of claim 1 , wherein suspension comprises a sweetener that is glucose, fructose, sucrose, xylitol, maltodextrin, polydextrose, glycerin, inulin, maltol, salts of acesulfame, alitame, aspartame, neotame, cyclamate salts, sucralose, sorbitol, saccharin and its salts, or a combination thereof.

13. The oral liquid suspension of claim 1 , wherein the defoamer is simethicone emulsion.

14. The oral liquid suspension of claim 1 , wherein the suspension comprises a buffer.

15. The oral liquid suspension of claim 14 , wherein the buffer is one or more of a citrate, tartrate, acetate, carbonate, phosphate, metaphosphate, glycerophosphate, polyphosphate, and pyrophosphate.

16. The oral liquid suspension of claim 14 , wherein the buffer is sodium citrate, sodium bicarbonate, or a combination thereof.

17. The oral liquid suspension of claim 1 , wherein the acid neutralizing agent is sodium bicarbonate.

Assignments (3)

Continuity (4)

References Cited (97)